It’s understandable to look at lower drug prices abroad with envy. But those low prices come at significant cost in terms of access. Importing those low prices via Most Favored Nation remains a bad deal for American patients.
It’s been a big year for revivals. There’s a new Jurassic Park movie, a reunion tour featuring 1990s rock band Oasis, and a Harry Potter television series in the works.
President Trump is also looking to revive some of the policies he tried to enact during his first term. He recently issued an executive order aimed at compelling pharmaceutical companies to sell drugs in the United States at the lowest price available in other developed countries. He upped the ante late last month by writing several major drug companies—including Pfizer, Eli Lilly, and Johnson & Johnson—informing them that they had to comply with his “Most Favored Nation” order.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
The Trump Administration Is Reviving Its Worst Drug Pricing Policies
Sally C. Pipes
It’s understandable to look at lower drug prices abroad with envy. But those low prices come at significant cost in terms of access. Importing those low prices via Most Favored Nation remains a bad deal for American patients.
It’s been a big year for revivals. There’s a new Jurassic Park movie, a reunion tour featuring 1990s rock band Oasis, and a Harry Potter television series in the works.
President Trump is also looking to revive some of the policies he tried to enact during his first term. He recently issued an executive order aimed at compelling pharmaceutical companies to sell drugs in the United States at the lowest price available in other developed countries. He upped the ante late last month by writing several major drug companies—including Pfizer, Eli Lilly, and Johnson & Johnson—informing them that they had to comply with his “Most Favored Nation” order.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.